

HEALTHY U MEDICAID

PRIOR AUTHORIZATION REQUEST FORM

LUPKYNIS™

For authorization, please answer each question and fax this form PLUS chart notes back to the Healthy U Prior Authorization Department at 385-425-4052.

Failure to submit clinical documentation to support this request will result in a dismissal of the request.

If you have prior authorization questions, please call for assistance: 385-425-5094

Disclaimer: Prior Authorization request forms are subject to change in accordance with Federal and State notice requirements.

Date:	Member Name:	ID#:
DOB:	Gender:	Physician:
Office Phone:	Office Fax:	Office Contact:
Height/Weight:		
<p><i>Member must try formulary preferred drugs before a request for a non-preferred drug may be considered. If treatment with preferred products has not been successful, you must submit which preferred products have been tried, dates of treatment, and reason for failure. Reasons for failure must meet the Health Plan medical necessity criteria.</i></p>		
<p>Product being requested: <input type="checkbox"/> Lupkynis™ (voclosporin)</p>		
<p>Dosing/Frequency: _____</p>		

If the request is for reauthorization, proceed to reauthorization section.

Questions	Yes	No	Comments/Notes
1. Is the request made by, or in consultation with, a nephrologist or rheumatologist?	<input type="checkbox"/>	<input type="checkbox"/>	
2. Does documentation show the member has autoantibody-positive systemic lupus erythematosus (SLE), defined as anti-nuclear antibodies [ANA] greater than the laboratory reference range and/or anti-double-stranded DNA [anti-dsDNA] greater than 2 times the laboratory reference range?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
3. Does documentation include a kidney biopsy showing a histological diagnosis of lupus nephritis Class III, IV, or V?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
4. Is the member's recent eGFR ≥ 45 mL/min/1.73m ² ?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
5. Does the member have a history of kidney transplant?	<input type="checkbox"/>	<input type="checkbox"/>	
6. Has the member had a trial and failure, or contraindication/intolerance, to Benlysta (belimumab)?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
7. Does documentation show Lupkynis™ will be used concurrently with mycophenolate or azathioprine AND a systemic steroid?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
8. For women of childbearing potential, does the member have a negative serum pregnancy test at screening and negative urine pregnancy test at baseline?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation

REAUTHORIZATION

1. Is the request for reauthorization of therapy?	<input type="checkbox"/>	<input type="checkbox"/>	
---	--------------------------	--------------------------	--

2. Has the member been compliant with background immunosuppressive therapy?	<input type="checkbox"/>	<input type="checkbox"/>	
3. Has the member had a positive response to Lupkynis™, such as improvement or stability in renal function, reduction in flares, reduction in corticosteroid dose, decrease of anti-dsDNA titer and/or improvement in complement levels?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
What medications and/or treatment modalities have been tried in the past for this condition? Please document name of treatment, reason for failure, treatment dates, etc.			
Additional information:			
Physician Signature:			

**** Failure to submit clinical documentation to support this request will result in a dismissal of the request. ****

Policy: PHARM-HU-118
 Origination Date: 01/01/2022
 Reviewed/Revised Date: 05/17/2023
 Next Review Date: 05/17/2024
 Current Effective Date: 06/01/2023

Confidentiality Notice

This document and any accompanying document contain confidential information and is intended for the use of the individual or entity named on this transmission sheet. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this information is strictly prohibited and the document should be returned to this office immediately. If you have received this facsimile in error, please notify us by telephone immediately and destroy document received.